2025-08-28
Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth
Viva Biotech will continue to strengthen the construction of its one-stop innovative novel drug R&D platform and manufacturing service platform.